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STRATEGIES TO PREDICT TREATMENT RESPONSE AND 
SELECT THERAPIES IN METASTATIC BREAST CANCER 
PATIENTS USING A NEXT GENERATION SEQUENCING 
(NGS) MULTI-GENE PANEL 
INTRODUCTION 
 
The standard of care for many 
patients with advanced breast 
cancer (BC )is gradually 
evolving from empirical 
treatment based on clinical-
pathological characteristics to 
the use of targeted approaches 
based on the molecular profile 
of the tumor.  
In the last decade, an 
increasing number of 
molecularly targeted drugs 
have been developed for the 
treatment of metastatic BC. 
These drugs target specific 
molecular abnormalities that 
confer to cancer cells a survival 
advantage [1]. Interestingly, 
the ability to perform multi-
gene testing for a range of 
molecular alterations may 
provide an opportunity to 
clarify the mechanisms of 
treatment response, to find the 
strategies to overcome 
treatment resistance and thus, 
to identify patients who are 
more likely to develop relapse 
and who may be candidates for 
matched targeted therapies   
[2-3].  
The main aim of this study is to 
find prognostic and predictive 
molecular biomarkers for the 
management of metastatic BC 
patients in clinical practice.  
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 PREDICT TREATMENT RESPONSE AND SELECT THERAPIES IN METASTATIC BREAST CANCER PATIENTS USING NGS 
MATERIALS AND 
METHODS 
The amplicon-sequencing 
analyses took advantage of the Ion 
AmpliSeq™ technology (Thermo 
Fisher, Waltham, MA, USA). A 
custom panel was designed with 
the help of the Designer online 
tool (www.ampliseq.com), 
which was employed to generate 
optimized primers encompassing 
the coding DNA sequences (with 
100bp of exon padding and the 
UTRs regions) of 25 genes in the 
Human Reference Genome 
(hg19); these genes were selected 
searching and screening scientific 
literature for treatments 
resistance in BC and are reported 
in Table 1. Primer pairs were 
divided into two pools to 
optimize multiplex PCR 
conditions and the coverage, that 
assessed to 89.02%. The 
customized Ion AmpliSeq panel 
was employed on samples from 7 
primary BC samples and matched 
metastatic sites (3 skin, 3 lymph 
node and 1 lung metastases). 
They were all processed using the 
Ion AmpliSeq Library Kit 2.0, 
starting from 15 nanograms of 
FFPE extracted DNA/pool. 
Samples were barcoded with the 
Ion Express Kit to optimize 
matched patients pooling on the 
same 318 Chip v2 sequencing 
chip. The template-positive Ion 
Sphere Particles were sequenced 
on a Personal Genome Machine 
(Thermo Fisher, Waltham, MA, 
USA) 
The mutation profiles of paired primary and 
secondary tumors of the seven patients enrolled in 
this study are presented in Table 2. Ten different 
genes (PTEN, PIK3CA, mTOR, ERBB2, ERBB3, 
MET, INPP4B, MAP2K1, CDK6, KRAS) in 6 
different patients showed possible damaging 
variants as shown in Table 2.  
  
• Four patients (number 1, 3, 5 and 6) showed no 
additional or different mutations in secondary 
tumors if compared to primary samples.  
•  In patient number 2, the metastatic site 
presented new mutations if compared to the 
primary tumor.  
•  Finally in patient number 4 and 7 we did not 
detect in metastases some of the mutations 
found in the primary tumor.  
 
RESULTS 
 
TABLE 1. NGS targeted panel of 25 genes involved in 
pathways of resistance to endocrine and targeted treatments 
 
EGFR ERBB2 ERBB3 UGF1R FGFR1 
MET AKT1 PDK1 MTOR PIKECA 
PIK3R1 PTEN INPP4B BRAF KRAS 
MEK1 MEK2 ERK1 ERK2 CCDN1 
CCDN2 CCDN3 CDK4 CDK6 ESR1 
 
 3 
DISCUSSION 
In 5 patients (71,4%) the mutational status of primary tumor could explain treatment resistance and thus 
predict relapse, in one patient the mutational status of the new subclones could be relevant for guiding 
differently the subsequent treatment choices.  
In 2 patients (28,5%) we were not able to detect in metastases some of the mutations found in the primary 
tumor. This could be explained by considering the clonal evolution of metastases.  
These preliminary data suggest that the multi-gene panel analysis of primary and secondary tumors may help 
clinicians: 
• in discriminating BC patients HR+ and/or HER2+ with mutations predicting an increased risk of adjuvant 
treatment resistance and thus relapse 
• in guiding treatment selection strategies in the metastatic setting. 
The study is still open and we are currently recruiting other patients. 
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